Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2015

View Archived Issues

Nucleic acid antibody prophylaxis as an antiviral immunotherapy for dengue

FDA OOPD awards grant to support development of ADXS-HPV in throat cancer

PeptiDream and Sanofi establish peptide discovery collaboration

RaQualia selects RQ-00433412 for preclinical development in cancer cachexia

STAT2 regulates mitochondrial fission

Baxalta files for U.S. approval of 20% immunoglobulin subcutaneous

XenoPort reports phase II study data for XP-23829

P2X7R antagonist reduces neuronal death in epilepsy model

Amicus Therapeutics to submit NDA for migalastat for Fabry disease

Teijin Pharma and Amgen report ROR-gamma antagonists

BARDA funding awarded to Crucell Holland to accelerate Ebola vaccine program

Laboratoire Biodim discloses dltA inhibitors

Glenmark Pharmaceuticals' GBR-1302 to enter phase I trials

Ono Pharmaceutical describes EP2 agonists

Jiangsu Ascentage Biomed Development reports ALK inhibitors

Andexanet alfa achieves rapid and sustained reversal of rivaroxaban in phase III trial

Sichuan Haisco Pharmaceutical reports phosphoramidate antivirals

Mylan initiates offer for Perrigo shares, Perrigo tells shareholders to wait

RepliCel starts phase I trial of autologous fibroblast therapy RCS-01

AZTherapies initiates phase III study of ALZT-OP1 for early Alzheimer's disease

Seegene and BD Life Sciences collaborate to develop multiplex molecular diagnostic assays

Bionomics reports data from phase I trial of BNC-210 for anxiety and depression

Depomed urges shareholders to reject Horizon Pharma's unsolicited exchange offer

Hemostemix signs strategic alliance agreement with Hemostemix Asia for ACP-01

Cotranstplantation of islets and dental pulp stem cells improves survival in diabetic mice

ALCAM mediates late kidney complications of diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...